Tristel, a manufacturer of infection prevention and contamination control products, saw profit for the year to end of June rise after undertaking a set of restructuring measures.An 18-month restructuring plan, the creation of new products and investment in the disinfection market led the firm to be "in good shape".The company's revenues rose 28% to £13.5m this year compared to £10.6m in the year before. As a results the group managed to boost profits before tax to £1.8m from £0.48m the prior year.Tristel was able to overturn the decline on sales of its legacy endoscopy products by replacing them for new ones. These products are mostly disinfectants of medical instruments used in hospitals out-patient departments."Our market environment globally is moving increasingly in the direction of a more data driven approach to disinfection," chairman Christopher Samler said.Earnings per share also increased to 3.25p for the full year compared to last year's 3.16p, while cash and equivalents increased to £2.6m from £0.6m in the year before.Chief executive Paul Swinney said: "By focusing upon the group's core competence of innovation and product development, and with a disciplined and targeted approach, I feel confident that Tristel will deliver continued growth into the future."FinnCap analysts said the proposed dividend of 1.6p is "a significant improvement" on the 0.4p last year, and see "potential for a progressive dividend policy to be maintained".Shares were down 0.94% to 73.8p on Monday at 16:16.